Up 35% on Buyout: InterMune inc Investor Key Takeaways

FDA's rejection of InterMune's Esbriet hurt investors, but Roche clearly thinks the drug will be approved.

Aug 25, 2014 at 4:38PM

Source: InterMune.

The Food and Drug Administration should have approved InterMune's (NASDAQ:ITMN) Esbriet four years ago; Roche's $8.3 billion buyout of InterMune announced yesterday proves that.

Esbriet still isn't approved in the U.S., but Roche clearly doesn't seem worried since it's willing to make the purchase at this point and for a 63% premium on the price before rumblings of a potential InterMune buyout started about two weeks ago.

A walk down InterMune's roller coaster stock chart
Itmn Chart

ITMN data by YCharts

You'll recall -- or maybe not since it was so long ago -- InterMune ran two phase 3 trials testing Esbriet in patients with the lung disease, idiopathic pulmonary fibrosis, or IPF. Only one of the two trials showed a statistically significant difference in the primary endpoint -- a measurement of lung capacity -- compared to placebo after 72 weeks.

Without any approved drugs for IPF, the doctors on the FDA advisory panel recommended approving Esbriet. The data was far from clean, but nine of the 12 panel members concluded that something is better than nothing.

The FDA wasn't as lenient. The data-driven agency ignored the committee's recommendation and rejected Esbriet in 2010, demanding another trial to prove that Esbriet really helps IPF patients.

Its European counterpart followed the something-is-better-than-nothing philosophy. In late 2010, the Committee for Medicinal Products for Human Use (CHMP) recommended approving Esbriet. A CHMP recommendation is akin to an approval because the European Commission is just a rubber stamp.


Source: Sebastien Wiertz via flickr.

Fast forward to earlier this year when InterMune reported that Esbriet passed the confirmatory clinical trial.

There seems to be little doubt in the minds of Roche's executives that the FDA will approve Esbriet on or before the November 23 PDUFA date. The only question is whether the approval will come with a sticky note attached apologizing for the first rejection.

Lessons from InterMune's comeback
There are a few lessons here:

Patience prevails. If you held onto InterMune through the rollercoaster, you're sitting on a 5-year return around 370%, beating the Nasdaq Biotechnology Index's approximately 260% 5-year return. Of course you might have spent all the additional gain on celebratory bubbly and antacids in the interim.

Understanding regulators' standards is the key to success. You could have done even better if you sold after the advisory panel meeting before the FDA handed down the rejection and repurchased shares during one of the subsequent dips.

Unfortunately, predicting regulators' actions can be difficult because they're constantly changing. I think the FDA has actually gotten a little more lenient with its data requirements in the last five years. If InterMune came to the FDA today with mixed phase 3 data, I could see the agency giving Esbriet an accelerated approval, requiring a new trial to gain full approval.

The FDA rejection was very costly. While investors are up about 370% over five years, InterMune's market cap is more than 1,000% higher than it was five years ago. Investors have a smaller piece of that pie -- and thus a smaller share price gain -- because InterMune had to sell additional shares to pay for the additional trial.

And not only would investors not have had the dilution if the FDA had approved Esbriet in 2010, but InterMune would have four years of sales under its belt, potentially propelling it to blockbuster status and InterMune's valuation well above the $8.3 billion that Roche is paying.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information